Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

472.09 +3.24 (+0.69%)
Streaming Delayed Price Updated: 3:51 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 Next >
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
From Vertex Pharmaceuticals
Via Business Wire
Vertex Reports Second Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce Second Quarter 2024 Financial Results on August 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Participate in Upcoming June Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Jennifer Schneider Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. 
Via MarketBeat
Topics ETFs
Vertex Reports First Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
From Alpine Immune Sciences, Inc.
Via Business Wire
Vertex to Announce First Quarter 2024 Financial Results on May 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains 
Via MarketBeat
Topics ETFs
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease”
Via AB Newswire
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Vertex to Participate in Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.